Wells Fargo Cuts argenx (ARGX) Price Target to $1,336
Key Points
- Wells Fargo maintained an Overweight rating on argenx SE while lowering its price target from $1,356.00 to $1,336.00 on October 23, 2026.
- Wells Fargo's $1,336 price target implies 52.55% upside from argenx SE's ($ARGX) current $875.76 share price.
- The biopharmaceutical company trades with a trailing twelve-month revenue of $5.32 billion and a P/E ratio of 30.3.
- Other Wall Street firms including RBC Capital and Evercore ISI Group also recently updated their views on the stock.
Get argenx SE text alerts
We text you when insiders, Congress, analysts or big funds move on $ARGX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures
Wells Fargo maintained its Overweight rating on argenx SE [ARGX] on October 23, 2026, while lowering its price target from $1,356.00 to $1,336.00. The research note arrived as shares of the biopharmaceutical company traded around $875.76, up about 0.8% from an event-day close of $869.07 on October 23, 2026.
ARGX
argenx SE
Wells Fargo vs. the S&P 500
Hypothetical returns from Wells Fargo's disclosed trades, not real profit or advice. How we model this.
Wells Fargo's Call on argenx SE
In its October 23 note, Wells Fargo kept its positive stance on the drug developer while trimming the target slightly from its previous level of $1,356.00. Earlier in the month on October 14, the firm had maintained the same Overweight rating with a $1,355.00 target, demonstrating steady conviction in the company's treatment pipeline.
Other Institutional Activity in argenx SE
Large investment firms have adjusted their holdings in argenx significantly in recent reporting periods. Jupiter Topco LLC grew its holdings by 1,237,008 shares, ending with 2,474,015 shares worth about $2,150,092,234.00. Artisan Partners Limited Partnership grew its holdings by 40,810 shares, ending with 1,508,778 shares worth about $1,311,233,707.00. Avoro Capital Advisors LLC kept its stake steady at 1,000,000 shares worth about $869,070,007.00, while RTW Investments LP held steady with 709,446 shares valued at roughly $616,558,240.00.
argenx SE Stock Down 1.6%
The stock recently changed hands at $875.76, sitting about 18.4% below its 52-week high of $1,072.75 and roughly 32.3% above its 52-week low of $661.85. The shares trade below their 50-day moving average of $952.65 but remain above their 200-day moving average of $852.26.
$ARGX price target
argenx SE daily closes and this analyst's $1,336 target. Not advice.
Recent Earnings
The company generated trailing twelve-month revenue of $5.32 billion alongside earnings of $28.87 per share. Profitability remains solid, anchored by a net margin of 32.3% and a return on equity of 23.6%.
Analysts Set New Price Targets
Wall Street firms have actively reviewed the stock alongside Wells Fargo. On October 20, 2026, RBC Capital maintained an Outperform rating while adjusting its price target from $1,100.00 to $1,025.00. On October 23, 2026, Evercore ISI Group maintained an Outperform rating and raised its target from $1,078.00 to $1,090.00. On the same day, Baird maintained a Neutral rating while lifting its target from $823.00 to $861.00. Overall, the stock carries a consensus buy rating among 23 analysts, with a mean price target of $1,150.91.
About argenx SE
Headquartered in Amsterdam, argenx SE is a commercial-stage biotechnology firm that researches and markets therapies for autoimmune conditions. Its primary commercial products include VYVGART and VYVGART HYTRULO, which treat generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. The ongoing commercial rollout of these antibody-based treatments drives the company's financial growth.
Bottom Line
Investors are watching upcoming earnings reports and prescription trends for the company's flagship antibody treatments to see if sales continue to support Wall Street's growth expectations. No additional regulatory filings or corporate announcements accompanied the rating update.
Related Filing Alerts
Source: Wells Fargo's rating change on $ARGX (Oct 23, 2026). Written by software, not financial advice. How we make alerts